EUVIMEDEUVIMED entdecken
Crossref

Anifrolumab (Saphnelo)

CDA-AMC

Canadian Journal of Health Technologies · 20.10.2026 · 6 (10)

DOI: 10.51731/cjht.2026.1545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 20.10.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses anifrolumab (SAPHNELO), 120 mg in 0.8mL, solution for injection, sub-cutaneous. Indication: Is indicated in addition to standard therapy for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus (SLE).

Zitieren

APA

CDA-AMC (2026). Anifrolumab (Saphnelo). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1545

Vancouver

CDA-AMC. Anifrolumab (Saphnelo). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1545

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Anifrolumab (Saphnelo)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {10},
  doi = {10.51731/cjht.2026.1545}
}
Kostenlos starten →